Kathleen Ford serves as the Chief Operating Officer at KURA ONCOLOGY INC, a biopharmaceutical company focused on developing innovative cancer therapies. With over two decades of experience in the biotechnology and pharmaceutical industries, Ford has established herself as a seasoned executive with a proven track record of driving operational excellence and strategic growth. Prior to joining KURA ONCOLOGY INC, she held various leadership positions at prominent companies such as Genentech and Amgen, where she honed her skills in managing complex drug development programs and overseeing global operations. At KURA ONCOLOGY INC, Ford plays a pivotal role in steering the company's day-to-day operations and long-term strategic initiatives. Her responsibilities include overseeing the development and execution of the company's clinical and commercial strategies, ensuring that KURA ONCOLOGY INC remains at the forefront of cancer research and treatment. Ford's leadership has been instrumental in advancing the company's pipeline of novel oncology therapies, which aim to address unmet medical needs and improve patient outcomes. Her ability to navigate the challenges of drug development and bring innovative treatments to market has been a key factor in the company's success. Throughout her career, Ford has been recognized for her contributions to the field of oncology and her dedication to improving patient care. She has been an active member of several professional organizations and has served on numerous advisory boards, sharing her expertise and insights with the broader scientific community. Ford's commitment to excellence and her passion for making a difference in the lives of cancer patients continue to drive her work at KURA ONCOLOGY INC, where she remains focused on advancing the company's mission of transforming the treatment landscape for cancer.